Patient-Derived Xenograft Models (PDX) for Preclinical Research

Patient-derived xenograft (PDX) models comprise the most effective class of preclinical models for phenocopying cancer intratumor heterogeneity, preserving intrinsic tumor architectures, and studying drug response and resistance.

Oncology researchers have used PDX models to develop therapies for a myriad of cancer types.

PDX models are established through subcutaneous injection of tumor cells and tissues from patients. The PDX models shown superiority, compared to cell line-derived models, in recapitulating cancer phenotypes seen in human patients.

PDX models retain the genomic features of patients’ tumors across different tumor stages and subtypes, regardless of treatment method.

PDX models have become the gold standard for oncology studies, particularly for preclinical trials of novel drugs, validation of novel drug combinations, screening with drug-sensitive patients, exploration of drug resistance mechanisms, and drug efficacy testing.

• 

  Medicilon's PDX Models

  The Patient-Derived Tumor Xenograft (PDX): model is established by directly transplanting the patient's tumor tissue into immunodeficient mice. The characteristics of most primary tumors in histopathology, molecular biology and gene level, ensuring relatively reliable predictions of clinical efficacy . Therefore, the platform is widely used in the development of new drugs, especially in the selection of patients in clinical trials of target drugs and the study of predictive biomarkers.

  As of July 2024, Medicilon offers over 400 tumor evaluation models, including more than 100 PDX models. Our scientists are empowering innovative therapies to comprehensively evaluate and study immuno-oncology.